Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?

Lancet Gastroenterol Hepatol. 2019 Aug;4(8):575-577. doi: 10.1016/S2468-1253(19)30148-7. Epub 2019 May 17.

Authors

Joseph W Franses¹, Theodore S Hong², Andrew X Zhu³

Affiliations

¹ Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA; Dana-Farber Cancer Institute, Boston, MA, USA.
² Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA.
³ Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA. Electronic address: [email protected].

PMID: 31109809
DOI: 10.1016/S2468-1253(19)30148-7

No abstract available

Publication types

Comment

MeSH terms

Biliary Tract Neoplasms*
Cisplatin*
Deoxycytidine / analogs & derivatives
Gemcitabine
Humans
Japan
Neoplasm Recurrence, Local
Nivolumab

Substances

Deoxycytidine
Nivolumab
Cisplatin
Gemcitabine